Pricing Log in Create free account
Saturday 7 November 2026 Export QURE’s income statement to Excel — free account

uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.

Revenue
+40.4%
EPS
+36.5%
Free cash flow
+27.7%
Total debt
−2.96%

Quarter to September 2026, against a year earlier

21.62 0.61 +2.90%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 20.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 2 2 8 — 1 18 1 — — — —
Insider Ownership 7.78%

Capital & Financial Ratios $m

Size
Market Cap 1,460.00
Revenue ttm 20.17
Net income ttm (232.90)
Free cash flow ttm (192.96)
Net debt Q (618.12)
Valuation
P/E 0.00
Forward P/E (6.63) (negative: loss-making)
Price / sales 74.94 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.13
Financial health
Current ratio Q 11.52 (at or above 1.5: strong)
Debt / equity Q 0.17 (at or below 0.5: strong)
Interest coverage Q (3.63)
Growth
Revenue growth Q +40.39% (above 0%: growing)
Operating income growth Q −3.81% (below 0%: shrinking)
EPS, this year −9.60% (below 0%: weak)
EPS, next year A +23.05% (at or above 15%: strong)
Revenue, next year A +45.50% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +29.42% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 44.7×, against a ten-year median of 16.3×; over the ten years it ranged from −16.4× in 2024 to 428× in 2020.
P/S against its own 10 years 67.34%
10-year low 10-year high
P/B against its own 10 years 49.58%
10-year low 10-year high
EV/Sales against its own 10 years 61.63%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 618 368 623 668
Receivables 4 6 6 5
Inventory 12 — — —
Other 3 8 7 10
652 390 656 693
2023 2024 2025 Q'26
Payables 7 7 5 6
ST’ Debt — — — —
Other 28 — 13 —
74 40 63 60

Compound Annual Growth %

10y 5y 3y
Sales 4.29% (15.57%) (46.73%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 4.51% (4.00%) (25.24%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.84 Actual −0.88

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.93 −0.56 Beat by 0.37
Q1 FY26 −0.88 −0.85 Beat by 0.03
Q2 FY26 −0.81 −1.22 Miss by 0.41
Q3 FY26 −0.84 −0.88 Miss by 0.04
Q4 FY26 −0.88 — Reports 1 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.85) (1.22) (0.88) — —
’25 (0.82) (0.69) (1.38) (0.56) (3.46)
’24 (1.36) (1.16) (0.91) (1.50) (4.92)
’23 (1.63) (1.44) (1.88) (1.53) (6.47)
’22 (1.00) (0.84) (1.02) 0.15 (2.71)
’21 (0.91) 8.51 (0.79) 0.17 7.04
’20 (0.63) (0.96) (1.21) (0.01) (2.81)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 4 6 5 — —
’25 2 5 4 6 16
’24 8 11 2 5 27
’23 5 2 1 7 16
’22 2 0 1 103 106
’21 0 464 2 58 524
’20 0 2 2 34 38
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (29) (48) — —
’25 (44) (40) (16) (78) (178)
’24 (61) (33) (37) (53) (183)
’23 (78) (57) 39 (50) (146)
’22 (26) (16) (49) (55) (145)
’21 (41) 416 (40) (47) 288
’20 (33) (30) (35) (37) (135)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (29) (48) — —
’25 (44) (40) (16) (78) (178)
’24 (63) (33) (37) (53) (186)
’23 (81) (58) 37 (52) (153)
’22 (30) (20) (53) (60) (163)
’21 (45) 414 (48) (51) 271
’20 (36) (32) (37) (40) (144)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 25 13 11 7 38 524 106 16 27 16 20 (4.8%) 23 107 354 +180.2%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 96.86 13.98 32.42 89.53 93.85 (10.5) pt
EBT (72) (79) (83) (124) (141) 333 (128) (307) (237) (193) (234) +11.6%
EBT margin, % (287.79) (606.23) (736.20) (1,705.82) (377.04) 63.51 (120.45) (1,934.97) (874.39) (1,201.02) (1,159.36) (913.2) pt
Net income (73) (79) (83) (124) (125) 330 (127) (308) (240) (199) (233) +11.7%
Per share, $
Per share, $ Revenue 1.00 0.49 0.32 0.18 0.84 11.39 2.28 0.33 0.56 0.28 0.29 (13.2%)
Earnings (2.93) (2.94) (2.34) (3.11) (2.81) 7.17 (2.71) (6.47) (4.92) (3.46) (3.51) +1.9%
Cash flow (2.88) (2.38) (2.13) (2.47) (3.03) 6.26 (3.10) (3.06) (3.76) (3.09) (2.75) +0.8%
Capex (0.69) (0.21) (0.12) (0.17) (0.21) (0.38) (0.38) (0.15) (0.07) (0.01) (0.01) (39.4%)
Free cash flow (3.57) (2.59) (2.25) (2.63) (3.25) 5.88 (3.48) (3.21) (3.83) (3.10) (2.76) (1.5%)
Book value 2.54 3.31 5.04 8.08 5.49 12.96 10.19 4.36 (0.14) 3.46 4.22 +3.5%
Shares, m 25 27 36 40 44 46 47 48 49 58 64 +9.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 2.90 0.00 0.00 0.00 0.00 0.00 0.3
P/S 5.86 41.50 91.03 393.68 42.83 1.82 9.59 20.85 31.68 85.48 74.94 72.4
P/B 2.31 6.09 5.72 8.87 6.59 1.60 2.14 1.59 0.00 6.92 5.13 4.2
EV/Sales 1.38 30.93 74.08 347.87 37.47 0.97 7.31 (11.21) 20.32 50.40 44.70 56.0
EV/FCF (0.39) (5.80) (10.41) (24.05) (9.74) 1.89 (4.72) 1.14 (2.93) (4.49) (4.62) (5.9)
Cash, $m
Cash, $m Operating cash flow (72) (64) (76) (99) (135) 288 (145) (146) (183) (178) (192) +10.5%
Capex (17) (6) (4) (7) (9) (17) (18) (7) (3) 0 (1) (33.5%)
Free cash flow (89) (70) (80) (105) (144) 271 (163) (153) (186) (178) (193) +8.0%
Balance, $m
Balance, $m Working capital 121 144 217 353 232 591 401 578 350 593 632 +19.3%
Net debt (112) (139) (191) (342) (209) (455) (250) (516) (316) (573) (618) +19.9%
Shareholders’ equity 64 89 180 323 244 596 476 208 (7) 199 295 +13.5%
Returns, %
Returns, % ROA (32.40) (39.64) (34.46) (34.38) (31.69) 57.34 (16.75) (40.15) (34.51) (28.81) (25.47) +3.6 pt
ROIC 0.00 0.00 0.00 0.00 (226.63) 138.19 (39.60) 0.00 0.00 0.00 0.00 0.0 pt
ROE (76.61) (103.61) (61.94) (49.42) (44.10) 78.50 (23.66) (90.24) (238.46) (207.10) (88.99) (130.5) pt
People
People Employees 251 202 212 248 332 463 501 480 209 221 — (1.4%)
Revenue/emp, $m 0.10 0.06 0.05 0.03 0.11 1.13 0.21 0.03 0.13 0.07 — (3.5%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

uniQure N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.5B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00% Compare
PGEN Precigen, Inc. $1.5B 60.3× 32.2× +2,437.58% (above 0%: growing) n/m +140.34% (above 0%: growing) 91.22% 52.13% Compare
NUVB Nuvation Bio Inc. $1.5B — (loss-making) — (loss-making) +242.61% (above 0%: growing) n/m +34.07% (above 0%: growing) 73.46% (93.90%) Compare
ADRX ADARx Pharmaceuticals, Inc. $1.5B — — — — — — — Compare
QURE uniQure N.V. $1.5B — (loss-making) — (loss-making) +40.39% (above 0%: growing) n/m +27.66% (above 0%: growing) 95.46% (1,019.63%)
IMCR Immunocore Holdings PLC Sponsored ADR $1.5B — (loss-making) — (loss-making) −1.42% (below 0%: shrinking) n/m +440.97% (above 0%: growing) 99.34% (13.31%) Compare
TYRA Tyra Biosciences, Inc. $1.4B — (loss-making) — — n/m −31.34% (below 0%: shrinking) 0.00% 0.00% Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR $1.4B — — — — +17.74% (above 0%: growing) — — Compare
OCUL Ocular Therapeutix, Inc. $1.4B — (loss-making) — (loss-making) +0.12% (above 0%: growing) n/m −25.35% (below 0%: shrinking) 85.08% (609.34%) Compare
Median of peers $1.5B — — +0.12% — +17.74% 79.27% (6.65%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.29m 7.17m 66.23
2024 3.08m 9.94m 47.66
2023 6.58m (1.40m) 18.74
2022 5.63m 6.96m 62.75
2021 5.10m 1.56m 57.40

Ownership

Directors and executive officers, together 4.65%
Avoro Capital Advisors LLC 9.76%
FMR LLC 9.61%
RTW Investments, LP 5.89%
Aberdeen Group plc 5.84%
G1 Execution Services LLC 5.61%
State Street corporation 5.13%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

uniQure N.V. (QURE) Latest News

4 Nov

Impact 4 · · Moby
Impact 4 · · GuruFocus.com transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat transcript
Impact 4 · · GlobeNewswire

2 Nov

Impact 4 · · Investing.com
Impact 4 · · GlobeNewswire

29 Oct

Impact 4 · · Simply Wall St.

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

7 Oct

Impact 4 · · Simply Wall St.

1 Oct

Impact 4 · · Simply Wall St.

30 Sep

Impact 4 · · Zacks
Impact 4 · · 24/7 Wall St.

29 Sep

Impact 4 · · MarketBeat
Impact 4 · · Benzinga
Impact 4 · · InvestorsHub
Impact 4 · · InvestorsHub
Impact 4 · · Barrons.com
Impact 4 · · Stocktwits
Impact 4 · · Investing.com
Impact 4 · · GlobeNewswire
Impact 3 · · Stocktwits

8 Sep

Impact 4 ·

3 Sep

Impact 4 ·
Impact 4 ·

2 Sep

Impact 5 ·
Impact 4 ·
Impact 3 · · Stocktwits

7 Aug

Impact 3 · · The Motley Fool transcript
stockrow.com/QURE · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com